Login Register Cart 0
Mini-Review Article

褪黑激素在子宫内膜癌中的分子生物学功能

卷 21, 期 5, 2020

页: [519 - 526] 页: 8

弟呕挨: 10.2174/1389450120666190927123746

价格: $65

conference banner
摘要

子宫内膜癌是女性中排名第五的癌症。 在发达国家，这一比率更高，在世界范围内，其发病率也在增加。 糖尿病，肥胖，高血压和动脉硬化是子宫内膜癌的主要危险因素。 褪黑激素是在松果体和松果外器官（如消化道，骨髓，视网膜等）中合成的激素。 有证据表明褪黑激素可能会抑制子宫内膜癌。 因此，本文的重点是综述这一杰出的证据，并概述褪黑激素抑制子宫内膜癌的分子和生物学机制。

关键词: 褪黑激素，妊娠，子宫内膜癌，细胞凋亡，肥胖，骨髓。

« Previous
图形摘要

[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[2]
Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001; 15(3): 341-54.
[http://dx.doi.org/10.1053/beog.2000.0180] [PMID: 11476557]
[3]
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366(9484): 491-505.
[http://dx.doi.org/10.1016/S0140-6736(05)67063-8] [PMID: 16084259]
[4]
Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG 2002; 109(3): 313-21.
[http://dx.doi.org/10.1111/j.1471-0528.2002.01088.x] [PMID: 11950187]
[5]
Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89(8): 1765-72.
[http://dx.doi.org/10.1002/1097-0142(20001015)89:8<1765:AID-CNCR17>3.0.CO;2-F] [PMID: 11042572]
[6]
Haltia UM, Bützow R, Leminen A, Loukovaara M. FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype. J Gynecol Oncol 2014; 25(1): 30-5.
[http://dx.doi.org/10.3802/jgo.2014.25.1.30] [PMID: 24459578]
[7]
Gredmark T, Kvint S, Havel G, Mattsson LA. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol 1995; 102(2): 133-6.
[http://dx.doi.org/10.1111/j.1471-0528.1995.tb09066.x] [PMID: 7756204]
[8]
Ushijima M, Yamakawa Y, Takagoshi Y, Maeda M, Oketani K, Katou K, et al. A case of serous adenocarcinoma of the endometrium in a coexistent pedunculated, prolapsed submucosal leiomyoma. Journal of the Japanese Society of Clinical Cytology 2011; 50: 355-9.
[http://dx.doi.org/10.5795/jjscc.50.355]
[9]
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15(1): 10-7.
[http://dx.doi.org/10.1016/0090-8258(83)90111-7] [PMID: 6822361]
[10]
Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12(2): 151-80.
[http://dx.doi.org/10.1210/edrv-12-2-151] [PMID: 1649044]
[11]
Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014; 71(16): 2997-3025.
[http://dx.doi.org/10.1007/s00018-014-1579-2] [PMID: 24554058]
[12]
Reiter RJ. Melatonin and human reproduction. Ann Med 1998; 30(1): 103-8.
[http://dx.doi.org/10.3109/07853899808999391] [PMID: 9556096]
[13]
Luchetti F, Canonico B, Betti M, et al. Melatonin signaling and cell protection function. FASEB J 2010; 24(10): 3603-24.
[http://dx.doi.org/10.1096/fj.10-154450] [PMID: 20534884]
[14]
Vijayalaxmi, Thomas CR, Jr., Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20: 2575-601.
[http://dx.doi.org/10.1200/JCO.2002.11.004]
[15]
Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res 1986; 3(4): 379-88.
[http://dx.doi.org/10.1111/j.1600-079X.1986.tb00760.x] [PMID: 3783419]
[16]
Touitou Y, Fèvre M, Bogdan A, et al. Patterns of plasma melatonin with ageing and mental condition: stability of nyctohemeral rhythms and differences in seasonal variations. Acta Endocrinol (Copenh) 1984; 106(2): 145-51.
[http://dx.doi.org/10.1530/acta.0.1060145] [PMID: 6539550]
[17]
Kivelä A, Kauppila A, Ylöstalo P, Vakkuri O, Leppäluoto J. Seasonal, menstrual and circadian secretions of melatonin, gonadotropins and prolactin in women. Acta Physiol Scand 1988; 132(3): 321-7.
[http://dx.doi.org/10.1111/j.1748-1716.1988.tb08335.x] [PMID: 3147572]
[18]
Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13(5): 1177-85.
[http://dx.doi.org/10.1016/0896-6273(94)90055-8] [PMID: 7946354]
[19]
Shiu SY, Ng N, Pang SF. A molecular perspective of the genetic relationships of G-protein coupled melatonin receptor subtypes. J Pineal Res 1996; 20(4): 198-204.
[http://dx.doi.org/10.1111/j.1600-079X.1996.tb00259.x] [PMID: 8836953]
[20]
Becker-André M, Wiesenberg I, Schaeren-Wiemers N, et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994; 269(46): 28531-4.
[PMID: 7961794]
[21]
Carlberg C, Wiesenberg I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. J Pineal Res 1995; 18(4): 171-8.
[http://dx.doi.org/10.1111/j.1600-079X.1995.tb00157.x] [PMID: 8531047]
[22]
Pablos MI, Reiter RJ, Ortiz GG, et al. Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int 1998; 32(1): 69-75.
[http://dx.doi.org/10.1016/S0197-0186(97)00043-0] [PMID: 9460704]
[23]
Song Y, Chan CW, Brown GM, Pang SF, Silverman M. Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J 1997; 11(1): 93-100.
[http://dx.doi.org/10.1096/fasebj.11.1.9034171] [PMID: 9034171]
[24]
Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 1993; 246(2): 89-96.
[http://dx.doi.org/10.1016/0922-4106(93)90084-M] [PMID: 8397097]
[25]
Hardeland R, Reiter RJ, Poeggeler B, Tan DX. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993; 17(3): 347-57.
[http://dx.doi.org/10.1016/S0149-7634(05)80016-8] [PMID: 8272286]
[26]
Reiter RJ, Guerrero JM, Garcia JJ, Acuña-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann N Y Acad Sci 1998; 854: 410-24.
[http://dx.doi.org/10.1111/j.1749-6632.1998.tb09920.x] [PMID: 9928448]
[27]
Tan DX, Manchester LC, Reiter RJ, Qi WB, Karbownik M, Calvo JR. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000; 9(3-4): 137-59.
[http://dx.doi.org/10.1159/000014635] [PMID: 10899700]
[28]
Cos S, Fernández F, Sánchez-Barceló EJ. Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci 1996; 58(26): 2447-53.
[http://dx.doi.org/10.1016/0024-3205(96)00249-4] [PMID: 8691990]
[29]
Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 1992; 64(3): 249-56.
[http://dx.doi.org/10.1016/0304-3835(92)90050-6] [PMID: 1638517]
[30]
Bartsch H, Bartsch C, Simon WE, Flehmig B, Ebels I, Lippert TH. Antitumor activity of the pineal gland: effect of unidentified substances versus the effect of melatonin. Oncology 1992; 49(1): 27-30.
[http://dx.doi.org/10.1159/000227005] [PMID: 1542489]
[31]
Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51(5): 1409-16.
[http://dx.doi.org/10.1093/jnci/51.5.1409] [PMID: 4357757]
[32]
Gonzalez R, Sanchez A, Ferguson JA, et al. Melatonin therapy of advanced human malignant melanoma. Melanoma Res 1991; 1(4): 237-43.
[http://dx.doi.org/10.1097/00008390-199111000-00003] [PMID: 1823632]
[33]
Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17(5): 1683-90.
[http://dx.doi.org/10.1523/JNEUROSCI.17-05-01683.1997] [PMID: 9030627]
[34]
Lissoni P, Mainini E, Rovelli F, et al. A clinical study of the pineal hormone melatonin in patients with growth hormone or prolactin secreting pituitary tumours. Eur J Med 1992; 1(7): 407-10.
[PMID: 1341480]
[35]
Fitzgerald TJ, Veal A. Melatonin antagonizes colchicine-induced mitotic arrest. Experientia 1976; 32(3): 372-3.
[http://dx.doi.org/10.1007/BF01940846] [PMID: 1253915]
[36]
Shellard SA, Whelan RD, Hill BT. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. Br J Cancer 1989; 60(3): 288-90.
[http://dx.doi.org/10.1038/bjc.1989.272] [PMID: 2789933]
[37]
Dai M, Cui P, Yu M, Han J, Li H, Xiu R. Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J Pineal Res 2008; 44(2): 121-6.
[http://dx.doi.org/10.1111/j.1600-079X.2007.00498.x] [PMID: 18289162]
[38]
Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008; 7(3): 189-203.
[http://dx.doi.org/10.1177/1534735408322846] [PMID: 18815150]
[39]
Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002; 11(12): 1531-43.
[PMID: 12496040]
[40]
Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992; 167(5): 1317-25.
[http://dx.doi.org/10.1016/S0002-9378(11)91709-8] [PMID: 1442985]
[41]
Ghanbari Andarieh M, Agajani Delavar M, Moslemi D, Esmaeilzadeh S. Risk factors for endometrial cancer: results from a hospital-based case-control study. Asian Pac J Cancer Prev 2016; 17(10): 4791-6.
[PMID: 27910901]
[42]
Setiawan VW, Yang HP, Pike MC, et al. Australian national endometrial cancer study group. type i and ii endometrial cancers: have they different risk factors? J Clin Oncol 2013; 31(20): 2607-18.
[http://dx.doi.org/10.1200/JCO.2012.48.2596] [PMID: 23733771]
[43]
Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE 2001; 2001(107): pe39.
[PMID: 11698691]
[44]
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27(2): 101-10.
[http://dx.doi.org/10.1385/ENDO:27:2:101] [PMID: 16217123]
[45]
Drazen DL, Nelson RJ. Melatonin receptor subtype MT2 (Mel 1b) and not mt1 (Mel 1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2001; 74(3): 178-84.
[http://dx.doi.org/10.1159/000054684] [PMID: 11528219]
[46]
Lotufo CM, Lopes C, Dubocovich ML, Farsky SH, Markus RP. Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur J Pharmacol 2001; 430(2-3): 351-7.
[http://dx.doi.org/10.1016/S0014-2999(01)01369-3] [PMID: 11711054]
[47]
Carrillo-Vico A, García-Mauriño S, Calvo JR, Guerrero JM. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J 2003; 17(6): 755-7.
[http://dx.doi.org/10.1096/fj.02-0501fje] [PMID: 12594180]
[48]
Shiu SY, Li L, Xu JN, Pang CS, Wong JT, Pang SF. Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res 1999; 27(3): 183-92.
[http://dx.doi.org/10.1111/j.1600-079X.1999.tb00614.x] [PMID: 10535768]
[49]
Osanai K, Kobayashi Y, Otsu M, Izawa T, Sakai K, Iwashita M. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells. Hum Cell 2017; 30(3): 209-15.
[http://dx.doi.org/10.1007/s13577-017-0169-7] [PMID: 28382516]
[50]
Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett 2009; 281(1): 1-7.
[http://dx.doi.org/10.1016/j.canlet.2008.11.002] [PMID: 19070424]
[51]
Sturgeon SR, Luisi N, Balasubramanian R, Reeves KW. Sleep duration and endometrial cancer risk. Cancer Causes Control 2012; 23(4): 547-53.
[http://dx.doi.org/10.1007/s10552-012-9912-2] [PMID: 22362059]
[52]
Sandyk R, Anastasiadis PG, Anninos PA, Tsagas N. Is the pineal gland involved in the pathogenesis of endometrial carcinoma. Int J Neurosci 1992; 62(1-2): 89-96.
[http://dx.doi.org/10.3109/00207459108999761] [PMID: 1342018]
[53]
de Almeida Chuffa LG, Seiva FRF, Cucielo MS, Silveira HS, Reiter RJ, Lupi LA. Mitochondrial functions and melatonin: a tour of the reproductive cancers. Cell Mol Life Sci 2019; 76(5): 837-63.
[http://dx.doi.org/10.1007/s00018-018-2963-0] [PMID: 30430198]
[54]
Ciortea R, Costin N, Braicu I, et al. Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats. Anticancer Res 2011; 31(8): 2637-43.
[PMID: 21778316]
[55]
Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res 2012; 52(3): 282-90.
[http://dx.doi.org/10.1111/j.1600-079X.2011.00940.x] [PMID: 22151118]
[56]
Winship AL, Van Sinderen M, Donoghue J, Rainczuk K, Dimitriadis E. Targeting interleukin-11 receptor-α impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo. Mol Cancer Ther 2016; 15(4): 720-30.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0677] [PMID: 26846819]
[57]
Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4(9)a011189
[http://dx.doi.org/10.1101/cshperspect.a011189] [PMID: 22952397]
[58]
Gao Y, Xiao X, Zhang C, et al. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways. J Pineal Res 2017; 62(2): 62.
[http://dx.doi.org/10.1111/jpi.12380] [PMID: 27865009]
[59]
Baharvand-Ahmadi B, Bahmani M, Tajeddini P, Naghdi N, Rafieian-Kopaei M. An ethno-medicinal study of medicinal plants used for the treatment of diabetes. J Nephropathol 2016; 5(1): 44-50.
[http://dx.doi.org/10.15171/jnp.2016.08] [PMID: 27047810]
[60]
Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000; 7(6): 444-58.
[http://dx.doi.org/10.1007/BF02253360] [PMID: 11060493]
[61]
Heidari F, Rabizadeh S, Mansournia MA, et al. Inflammatory, oxidative stress and anti-oxidative markers in patients with endometrial carcinoma and diabetes. Cytokine 2019; 120: 186-90.
[http://dx.doi.org/10.1016/j.cyto.2019.05.007] [PMID: 31100682]
[62]
Punnonen R, Kudo R, Punnonen K, et al. Activities of antioxidant enzymes and lipid peroxidation in endometrial cancer. Eur J Cancer 1993; 29A(2): 266-9.
[http://dx.doi.org/10.1016/0959-8049(93)90190-Q] [PMID: 8422294]
[63]
Księżakowska-Łakoma K, Żyła M, Wilczyński JR. Mitochondrial dysfunction in cancer. Przegl Menopauz 2014; 13(2): 136-44.
[http://dx.doi.org/10.5114/pm.2014.42717] [PMID: 26327844]
[64]
Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003; 112(5): 659-72.
[http://dx.doi.org/10.1016/S0092-8674(03)00150-8] [PMID: 12628186]
[65]
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35(4): 495-516.
[http://dx.doi.org/10.1080/01926230701320337] [PMID: 17562483]
[66]
Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60(7): 1407-26.
[http://dx.doi.org/10.1007/s00018-003-2319-1] [PMID: 12943228]
[67]
Cucina A, Proietti S, D’Anselmi F, et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009; 46(2): 172-80.
[http://dx.doi.org/10.1111/j.1600-079X.2008.00645.x] [PMID: 19175854]
[68]
Ferreira Cda S, Maganhin CC, Simoes Rdos S, Girao MJ, Baracat EC, Soares JM Jr. Rev Assoc Med Bras Melatonin: cell death modulator 1992; 2010(56): 715-8.
[69]
Lopes JR, Maschio LB, Jardim-Perassi BV, et al. Evaluation of melatonin treatment in primary culture of canine mammary tumors. Oncol Rep 2015; 33(1): 311-9.
[http://dx.doi.org/10.3892/or.2014.3596] [PMID: 25384569]
[70]
Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 2000; 28(4): 227-33.
[http://dx.doi.org/10.1034/j.1600-079X.2000.280405.x] [PMID: 10831158]
[71]
Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11(11): S37-43.
[http://dx.doi.org/10.1016/S0962-8924(01)02122-5] [PMID: 11684441]
[72]
Zitka O, Kukacka J, Krizkova S, et al. Matrix metalloproteinases. Curr Med Chem 2010; 17(31): 3751-68.
[http://dx.doi.org/10.2174/092986710793213724] [PMID: 20846107]
[73]
Paul S, Bhattacharya P, Das Mahapatra P, Swarnakar S. Melatonin protects against endometriosis via regulation of matrix metalloproteinase-3 and an apoptotic pathway. J Pineal Res 2010; 49(2): 156-68.
[http://dx.doi.org/10.1111/j.1600-079X.2010.00780.x] [PMID: 20609072]
[74]
Ahonen M, Baker AH, Kähäri VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58(11): 2310-5.
[PMID: 9622064]
[75]
Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999; 79(9-10): 1347-55.
[http://dx.doi.org/10.1038/sj.bjc.6690217] [PMID: 10188875]
[76]
Smith MR, Kung H, Durum SK, Colburn NH, Sun Y. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 1997; 9(10): 770-80.
[http://dx.doi.org/10.1006/cyto.1997.0233] [PMID: 9344510]
[77]
Bamberger AM, Milde-Langosch K, Rössing E, Goemann C, Löning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J Cancer Res Clin Oncol 2001; 127(9): 545-50.
[http://dx.doi.org/10.1007/s004320100255] [PMID: 11570575]
[78]
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348(17): 1625-38.
[http://dx.doi.org/10.1056/NEJMoa021423] [PMID: 12711737]
[79]
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34(35): 4225-30.
[http://dx.doi.org/10.1200/JCO.2016.69.4638] [PMID: 27903150]
[80]
Wolden-Hanson T, Mitton DR, McCants RL, et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141(2): 487-97.
[http://dx.doi.org/10.1210/endo.141.2.7311] [PMID: 10650927]
[81]
Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83(2): 461S-5S.
[http://dx.doi.org/10.1093/ajcn/83.2.461S] [PMID: 16470013]
[82]
Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000; 917: 376-86.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb05402.x] [PMID: 11268363]
[83]
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20(21): 4368-80.
[http://dx.doi.org/10.1200/JCO.2002.10.088] [PMID: 12409337]
[84]
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[85]
Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 2010; 11(2): 233-47.
[http://dx.doi.org/10.1517/14656560903451716] [PMID: 20088745]
[86]
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6): 401-10.
[http://dx.doi.org/10.1038/nrc1093] [PMID: 12778130]
[87]
Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod 2003; 69(3): 976-84.
[http://dx.doi.org/10.1095/biolreprod.103.015933] [PMID: 12773401]
[88]
Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007; 62(3): 179-213.
[http://dx.doi.org/10.1016/j.critrevonc.2007.01.006] [PMID: 17324579]
[89]
Jardim-Perassi BV, Arbab AS, Ferreira LC, et al. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS One 2014; 9(1)e85311
[http://dx.doi.org/10.1371/journal.pone.0085311] [PMID: 24416386]
[90]
Kim KJ, Choi JS, Kang I, Kim KW, Jeong CH, Jeong JW. Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J Pineal Res 2013; 54(3): 264-70.
[http://dx.doi.org/10.1111/j.1600-079X.2012.01030.x] [PMID: 22924616]
[91]
Mahecha AM, Wang H. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of endometrial cancer. OncoTargets Ther 2017; 10: 4617-24.
[http://dx.doi.org/10.2147/OTT.S132558] [PMID: 29033580]
[92]
Tian W, Teng F, Gao J, et al. Estrogen and insulin synergistically promote endometrial cancer progression via crosstalk between their receptor signaling pathways. Cancer Biol Med 2019; 16(1): 55-70.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0157] [PMID: 31119046]
[93]
Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91(13): 1131-7.
[http://dx.doi.org/10.1093/jnci/91.13.1131] [PMID: 10393721]
[94]
Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso-González C. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38(4): 217-22.
[http://dx.doi.org/10.1111/j.1600-079X.2004.00207.x] [PMID: 15813897]
[95]
Proietti S, Cucina A, Reiter RJ, Bizzarri M. Molecular mechanisms of melatonin’s inhibitory actions on breast cancers. Cell Mol Life Sci 2013; 70(12): 2139-57.
[http://dx.doi.org/10.1007/s00018-012-1161-8] [PMID: 23007844]
[96]
Martínez-Campa C, González A, Mediavilla MD, et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 2009; 101(9): 1613-9.
[http://dx.doi.org/10.1038/sj.bjc.6605336] [PMID: 19773750]
[97]
Cos S, González A, Güezmes A, et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 2006; 118(2): 274-8.
[http://dx.doi.org/10.1002/ijc.21401] [PMID: 16080194]
[98]
Ram PT, Dai J, Yuan L, et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002; 179(2): 141-50.
[http://dx.doi.org/10.1016/S0304-3835(01)00873-4] [PMID: 11888668]
[99]
Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 2015; 22(3): R183-204.
[http://dx.doi.org/10.1530/ERC-15-0030] [PMID: 25876649]
[100]
Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002; 13(6): 245-50.
[http://dx.doi.org/10.1016/S1043-2760(02)00603-3] [PMID: 12128285]

Rights & Permissions Print Cite
Article Metrics
46
4
Wayfinder Image
World Antimicrobial Awareness Week
World Prematurity Day
© 2024 Bentham Science Publishers | Privacy Policy